Managing Peripheral Vascular Disease
Guides PVD assessment with ABI interpretation and intervention referral criteria.
Why This Skill Exists
Peripheral artery disease (PAD) affects approximately 8.5 million Americans and is a marker of systemic atherosclerosis associated with a 3–6x increased risk of cardiovascular death. The 2024 ACC/AHA Guideline on Peripheral Artery Disease provides evidence-based recommendations for diagnosis, risk stratification, medical management, and revascularization. PAD is significantly underdiagnosed — up to 50% of patients are asymptomatic, and the ankle-brachial index (ABI), the primary screening tool, is underutilized in primary care.
Progression from claudication to critical limb-threatening ischemia (CLTI) carries a 25% risk of major amputation at one year. Timely diagnosis, aggressive risk factor modification, supervised exercise therapy, and appropriate revascularization referral can prevent limb loss and reduce cardiovascular events.
Checkpoint A: Pre-Draft Intake (Mandatory)
- What are the presenting symptoms — claudication (distance, location), rest pain, non-healing wounds, or asymptomatic? (default: "Symptoms not documented")
- What is the ankle-brachial index (ABI)? (default: "ABI not performed")
- Are pulse examinations documented (femoral, popliteal, DP, PT)? (default: "Pulses not documented")
- What is the Rutherford or Fontaine classification? (default: "Not classified")
- What are the cardiovascular risk factors — smoking, diabetes, hypertension, hyperlipidemia? (default: "Risk factors not assessed")
- Is the patient currently on antiplatelet and statin therapy? (default: "Medication status unknown")
- Has non-invasive vascular testing been performed beyond ABI (segmental pressures, duplex, CTA, MRA)? (default: "No additional imaging")
- Are there signs of critical limb-threatening ischemia — rest pain, tissue loss, gangrene? (default: "CLTI not assessed")
Documents to Request
- ABI measurement report (resting and post-exercise if available)
- Segmental pressure and pulse volume recording (PVR) study
- Duplex ultrasound of lower extremity arteries
- CTA or MRA of aorto-iliac and lower extremity vasculature (if intervention planned)
- Wound assessment documentation (if tissue loss present)
- Current medication list
- Lipid panel, HbA1c, renal function
- Smoking history and cessation status
- Prior vascular interventions or surgical reports
Step 1: Diagnosis and Severity Classification
ABI Interpretation:
| ABI Value |
Interpretation |
| > 1.40 |
Non-compressible (calcified vessels — common in diabetes, CKD); use TBI |
| 1.00–1.40 |
Normal |
| 0.91–0.99 |
Borderline; consider exercise ABI |
| 0.41–0.90 |
Mild-to-moderate PAD |
| ≤ 0.40 |
Severe PAD; high risk for CLTI |
Toe-Brachial Index (TBI): Use when ABI > 1.40 (non-compressible)
- Normal: ≥ 0.70
- Abnormal: < 0.70
Exercise ABI: Perform when resting ABI is borderline (0.91–0.99) and symptoms suggest PAD
- Drop in ABI ≥ 20% post-exercise = hemodynamically significant PAD
Fontaine / Rutherford Classification:
| Fontaine |
Rutherford |
Clinical |
Severity |
| I |
0 |
Asymptomatic |
Mild |
| IIa |
1 |
Mild claudication (> 200 m) |
Mild |
| IIb |
2–3 |
Moderate-to-severe claudication |
Moderate |
| III |
4 |
Rest pain |
Severe |
| IV |
5–6 |
Tissue loss (ulceration, gangrene) |
CLTI |
Step 2: Medical Management (All PAD Patients)
Cardiovascular Risk Reduction (Class I for all PAD patients):
| Intervention |
Target/Agent |
Evidence |
| Antiplatelet |
Aspirin 75–100 mg OR clopidogrel 75 mg daily |
Class I for symptomatic PAD |
| Statin |
High-intensity (atorvastatin 40–80 mg, rosuvastatin 20–40 mg) |
Class I; LDL < 70 mg/dL |
| BP control |
< 130/80 mmHg; ACEi/ARB preferred |
Ramipril (HOPE trial) |
| Smoking cessation |
Complete cessation; pharmacotherapy |
Single most impactful modifiable risk factor |
| Diabetes management |
HbA1c < 7%; SGLT2i if concurrent HF or CKD |
Reduce microvascular and macrovascular risk |
Antiplatelet Intensification:
- COMPASS trial: rivaroxaban 2.5 mg BID + aspirin 100 mg daily — superior to aspirin alone for PAD patients (28% reduction in MALE, 24% reduction in MACE)
- Consider COMPASS regimen for stable PAD without high bleeding risk
Claudication-Specific Therapies:
- Cilostazol 100 mg BID: phosphodiesterase-3 inhibitor; increases walking distance 40–60% (contraindicated in HF)
- Supervised exercise therapy: > structured walking program (30–45 min, 3×/week, minimum 12 weeks) — Class I, comparable benefit to revascularization for claudication
Step 3: Non-Invasive Vascular Testing
Segmental Pressures and Pulse Volume Recordings (PVR):
- Pressure gradient > 20 mmHg between adjacent segments = hemodynamically significant stenosis
- PVR waveform analysis: normal (sharp systolic peak, dicrotic notch) → progressive blunting indicates proximal disease
Duplex Ultrasound:
- Peak systolic velocity (PSV) ratio ≥ 2.0 at a stenosis = ≥ 50% stenosis
- PSV ratio ≥ 4.0 = ≥ 75% stenosis
- Absent flow = occlusion
CTA/MRA (Pre-Intervention Planning):
- CTA: preferred for calcified vessels, post-stent surveillance
- MRA: preferred when avoiding contrast (renal insufficiency) or iodine allergy; may overestimate stenosis
- Document: inflow (aorto-iliac), outflow (femoropopliteal, tibial), and runoff vessels
Step 4: Revascularization Decision-Making
Indications for Revascularization:
- Lifestyle-limiting claudication refractory to ≥ 3 months supervised exercise + pharmacotherapy
- Critical limb-threatening ischemia (rest pain, tissue loss)
- Acute limb ischemia (emergent)
CLTI WIfI Classification (Wound, Ischemia, Foot Infection):
- Wound grade (0–3): based on ulcer depth and gangrene extent
- Ischemia grade (0–3): based on ABI, ankle pressure, TP
- Foot infection grade (0–3): based on IDSA/IWGDF criteria
- WIfI stage predicts amputation risk and revascularization benefit
Revascularization Approach:
- Aorto-iliac disease: endovascular first (stenting) for focal lesions; surgical bypass (aortobifemoral) for extensive disease (TASC D)
- Femoropopliteal disease: endovascular for short lesions (< 25 cm); bypass for long occlusions with good conduit (autogenous vein preferred)
- Infrapopliteal disease: endovascular preferred for CLTI; balloon angioplasty ± drug-coated balloon
Acute Limb Ischemia (6 P's): Pain, Pallor, Pulselessness, Paresthesias, Paralysis, Poikilothermia
- Rutherford acute classification I–III determines urgency (viable → irreversible)
- Class I–IIa: anticoagulate with heparin; plan revascularization
- Class IIb: emergent revascularization (thrombectomy, thrombolysis, or bypass)
- Class III: irreversible; consider primary amputation
Step 5: Surveillance and Long-Term Management
Post-Revascularization Surveillance:
| Intervention |
Surveillance Protocol |
| Endovascular (stent) |
Duplex at 1, 6, 12 months, then annually |
| Surgical bypass (vein) |
Duplex at 1, 3, 6, 12 months, then annually |
| Surgical bypass (prosthetic) |
Duplex at 3, 6, 12 months, then annually |
Long-Term Monitoring:
- ABI measurement annually (or with symptom change)
- Cardiovascular risk factor reassessment at each visit
- Wound healing assessment for CLTI patients (weekly until healed)
- Foot care education and podiatric referral for diabetic patients
Checkpoint B: Post-Draft Alignment (Mandatory)
- Is the ABI documented and correctly interpreted?
- Is the severity classified by Fontaine/Rutherford?
- Are all cardiovascular risk reduction therapies addressed?
- Is supervised exercise therapy prescribed for claudication patients?
- Is the revascularization decision supported by objective hemodynamic and anatomic data?
Quality Audit
Guidelines
- Screen for PAD with ABI in patients ≥ 65, or ≥ 50 with diabetes or smoking history — PAD is underdiagnosed because many patients are asymptomatic.
- A non-compressible ABI (> 1.40) does NOT rule out PAD — use toe-brachial index, which is unaffected by medial calcification.
- Supervised exercise therapy is a Class I recommendation for claudication and should be offered before revascularization — studies show comparable improvement in walking distance.
- Cilostazol is the only FDA-approved medication for claudication symptom relief — do not use in patients with any degree of heart failure.
- The COMPASS trial regimen (rivaroxaban 2.5 mg BID + aspirin) should be considered for all stable PAD patients to reduce major adverse limb and cardiovascular events.
- For CLTI, multidisciplinary limb salvage teams (vascular surgery, podiatry, wound care, endovascular) improve outcomes — avoid uncoordinated referrals.
- Smoking cessation is the single most impactful intervention for PAD progression — document cessation counseling and pharmacotherapy at every encounter.
- Post-revascularization duplex surveillance is essential — early detection of restenosis allows reintervention before graft/stent failure and limb loss.
1---2name: managing-peripheral-vascular-disease3description: Guides PVD assessment with ABI interpretation and intervention referral criteria. Use when evaluating peripheral vascular disease, interpreting ABI studies, or managing claudication.4---5
6# Managing Peripheral Vascular Disease
7
8Guides PVD assessment with ABI interpretation and intervention referral criteria.
9
10## Why This Skill Exists
11
12Peripheral artery disease (PAD) affects approximately 8.5 million Americans and is a marker of systemic atherosclerosis associated with a 3–6x increased risk of cardiovascular death. The 2024 ACC/AHA Guideline on Peripheral Artery Disease provides evidence-based recommendations for diagnosis, risk stratification, medical management, and revascularization. PAD is significantly underdiagnosed — up to 50% of patients are asymptomatic, and the ankle-brachial index (ABI), the primary screening tool, is underutilized in primary care.
13
14Progression from claudication to critical limb-threatening ischemia (CLTI) carries a 25% risk of major amputation at one year. Timely diagnosis, aggressive risk factor modification, supervised exercise therapy, and appropriate revascularization referral can prevent limb loss and reduce cardiovascular events.
15
16---
17
18## Checkpoint A: Pre-Draft Intake (Mandatory)
19
201. What are the presenting symptoms — claudication (distance, location), rest pain, non-healing wounds, or asymptomatic? (default: "Symptoms not documented")
212. What is the ankle-brachial index (ABI)? (default: "ABI not performed")
223. Are pulse examinations documented (femoral, popliteal, DP, PT)? (default: "Pulses not documented")
234. What is the Rutherford or Fontaine classification? (default: "Not classified")
245. What are the cardiovascular risk factors — smoking, diabetes, hypertension, hyperlipidemia? (default: "Risk factors not assessed")
256. Is the patient currently on antiplatelet and statin therapy? (default: "Medication status unknown")
267. Has non-invasive vascular testing been performed beyond ABI (segmental pressures, duplex, CTA, MRA)? (default: "No additional imaging")
278. Are there signs of critical limb-threatening ischemia — rest pain, tissue loss, gangrene? (default: "CLTI not assessed")
28
29### Documents to Request
30
31- ABI measurement report (resting and post-exercise if available)
32- Segmental pressure and pulse volume recording (PVR) study
33- Duplex ultrasound of lower extremity arteries
34- CTA or MRA of aorto-iliac and lower extremity vasculature (if intervention planned)
35- Wound assessment documentation (if tissue loss present)
36- Current medication list
37- Lipid panel, HbA1c, renal function
38- Smoking history and cessation status
39- Prior vascular interventions or surgical reports
40
41---
42
43## Step 1: Diagnosis and Severity Classification
44
45**ABI Interpretation:**
46
47| ABI Value | Interpretation |
48|-----------|---------------|
49| > 1.40 | Non-compressible (calcified vessels — common in diabetes, CKD); use TBI |
50| 1.00–1.40 | Normal |
51| 0.91–0.99 | Borderline; consider exercise ABI |
52| 0.41–0.90 | Mild-to-moderate PAD |
53| ≤ 0.40 | Severe PAD; high risk for CLTI |
54
55**Toe-Brachial Index (TBI):** Use when ABI > 1.40 (non-compressible)
56- Normal: ≥ 0.70
57- Abnormal: < 0.70
58
59**Exercise ABI:** Perform when resting ABI is borderline (0.91–0.99) and symptoms suggest PAD
60- Drop in ABI ≥ 20% post-exercise = hemodynamically significant PAD
61
62**Fontaine / Rutherford Classification:**
63
64| Fontaine | Rutherford | Clinical | Severity |
65|----------|-----------|---------|----------|
66| I | 0 | Asymptomatic | Mild |
67| IIa | 1 | Mild claudication (> 200 m) | Mild |
68| IIb | 2–3 | Moderate-to-severe claudication | Moderate |
69| III | 4 | Rest pain | Severe |
70| IV | 5–6 | Tissue loss (ulceration, gangrene) | CLTI |
71
72---
73
74## Step 2: Medical Management (All PAD Patients)
75
76**Cardiovascular Risk Reduction (Class I for all PAD patients):**
77
78| Intervention | Target/Agent | Evidence |
79|-------------|-------------|---------|
80| Antiplatelet | Aspirin 75–100 mg OR clopidogrel 75 mg daily | Class I for symptomatic PAD |
81| Statin | High-intensity (atorvastatin 40–80 mg, rosuvastatin 20–40 mg) | Class I; LDL < 70 mg/dL |
82| BP control | < 130/80 mmHg; ACEi/ARB preferred | Ramipril (HOPE trial) |
83| Smoking cessation | Complete cessation; pharmacotherapy | Single most impactful modifiable risk factor |
84| Diabetes management | HbA1c < 7%; SGLT2i if concurrent HF or CKD | Reduce microvascular and macrovascular risk |
85
86**Antiplatelet Intensification:**
87- COMPASS trial: rivaroxaban 2.5 mg BID + aspirin 100 mg daily — superior to aspirin alone for PAD patients (28% reduction in MALE, 24% reduction in MACE)
88- Consider COMPASS regimen for stable PAD without high bleeding risk
89
90**Claudication-Specific Therapies:**
91- Cilostazol 100 mg BID: phosphodiesterase-3 inhibitor; increases walking distance 40–60% (contraindicated in HF)
92- Supervised exercise therapy: > structured walking program (30–45 min, 3×/week, minimum 12 weeks) — Class I, comparable benefit to revascularization for claudication
93
94---
95
96## Step 3: Non-Invasive Vascular Testing
97
98**Segmental Pressures and Pulse Volume Recordings (PVR):**
99- Pressure gradient > 20 mmHg between adjacent segments = hemodynamically significant stenosis
100- PVR waveform analysis: normal (sharp systolic peak, dicrotic notch) → progressive blunting indicates proximal disease
101
102**Duplex Ultrasound:**
103- Peak systolic velocity (PSV) ratio ≥ 2.0 at a stenosis = ≥ 50% stenosis
104- PSV ratio ≥ 4.0 = ≥ 75% stenosis
105- Absent flow = occlusion
106
107**CTA/MRA (Pre-Intervention Planning):**
108- CTA: preferred for calcified vessels, post-stent surveillance
109- MRA: preferred when avoiding contrast (renal insufficiency) or iodine allergy; may overestimate stenosis
110- Document: inflow (aorto-iliac), outflow (femoropopliteal, tibial), and runoff vessels
111
112---
113
114## Step 4: Revascularization Decision-Making
115
116**Indications for Revascularization:**
117- Lifestyle-limiting claudication refractory to ≥ 3 months supervised exercise + pharmacotherapy
118- Critical limb-threatening ischemia (rest pain, tissue loss)
119- Acute limb ischemia (emergent)
120
121**CLTI WIfI Classification (Wound, Ischemia, Foot Infection):**
122- Wound grade (0–3): based on ulcer depth and gangrene extent
123- Ischemia grade (0–3): based on ABI, ankle pressure, TP
124- Foot infection grade (0–3): based on IDSA/IWGDF criteria
125- WIfI stage predicts amputation risk and revascularization benefit
126
127**Revascularization Approach:**
128- Aorto-iliac disease: endovascular first (stenting) for focal lesions; surgical bypass (aortobifemoral) for extensive disease (TASC D)
129- Femoropopliteal disease: endovascular for short lesions (< 25 cm); bypass for long occlusions with good conduit (autogenous vein preferred)
130- Infrapopliteal disease: endovascular preferred for CLTI; balloon angioplasty ± drug-coated balloon
131
132**Acute Limb Ischemia (6 P's): Pain, Pallor, Pulselessness, Paresthesias, Paralysis, Poikilothermia**
133- Rutherford acute classification I–III determines urgency (viable → irreversible)
134- Class I–IIa: anticoagulate with heparin; plan revascularization
135- Class IIb: emergent revascularization (thrombectomy, thrombolysis, or bypass)
136- Class III: irreversible; consider primary amputation
137
138---
139
140## Step 5: Surveillance and Long-Term Management
141
142**Post-Revascularization Surveillance:**
143
144| Intervention | Surveillance Protocol |
145|-------------|---------------------|
146| Endovascular (stent) | Duplex at 1, 6, 12 months, then annually |
147| Surgical bypass (vein) | Duplex at 1, 3, 6, 12 months, then annually |
148| Surgical bypass (prosthetic) | Duplex at 3, 6, 12 months, then annually |
149
150**Long-Term Monitoring:**
151- ABI measurement annually (or with symptom change)
152- Cardiovascular risk factor reassessment at each visit
153- Wound healing assessment for CLTI patients (weekly until healed)
154- Foot care education and podiatric referral for diabetic patients
155
156---
157
158## Checkpoint B: Post-Draft Alignment (Mandatory)
159
1601. Is the ABI documented and correctly interpreted?
1612. Is the severity classified by Fontaine/Rutherford?
1623. Are all cardiovascular risk reduction therapies addressed?
1634. Is supervised exercise therapy prescribed for claudication patients?
1645. Is the revascularization decision supported by objective hemodynamic and anatomic data?
165
166---
167
168## Quality Audit
169
170- [ ] ABI measured and interpreted (or TBI if non-compressible)
171- [ ] Exercise ABI performed for borderline resting ABI
172- [ ] PAD severity classified (Fontaine/Rutherford)
173- [ ] Pulse examination documented (femoral through pedal)
174- [ ] Antiplatelet therapy initiated or documented
175- [ ] High-intensity statin prescribed
176- [ ] Smoking cessation addressed with pharmacotherapy options
177- [ ] BP target < 130/80 with ACEi/ARB preferred
178- [ ] Supervised exercise therapy prescribed for claudication
179- [ ] Cilostazol considered (no HF contraindication)
180- [ ] COMPASS regimen (low-dose rivaroxaban + aspirin) considered
181- [ ] Non-invasive imaging appropriate for clinical stage
182- [ ] CLTI assessed with WIfI classification if tissue loss present
183- [ ] Revascularization indication and approach documented
184- [ ] Surveillance protocol assigned post-intervention
185
186---
187
188## Guidelines
189
1901. Screen for PAD with ABI in patients ≥ 65, or ≥ 50 with diabetes or smoking history — PAD is underdiagnosed because many patients are asymptomatic.
1912. A non-compressible ABI (> 1.40) does NOT rule out PAD — use toe-brachial index, which is unaffected by medial calcification.
1923. Supervised exercise therapy is a Class I recommendation for claudication and should be offered before revascularization — studies show comparable improvement in walking distance.
1934. Cilostazol is the only FDA-approved medication for claudication symptom relief — do not use in patients with any degree of heart failure.
1945. The COMPASS trial regimen (rivaroxaban 2.5 mg BID + aspirin) should be considered for all stable PAD patients to reduce major adverse limb and cardiovascular events.
1956. For CLTI, multidisciplinary limb salvage teams (vascular surgery, podiatry, wound care, endovascular) improve outcomes — avoid uncoordinated referrals.
1967. Smoking cessation is the single most impactful intervention for PAD progression — document cessation counseling and pharmacotherapy at every encounter.
1978. Post-revascularization duplex surveillance is essential — early detection of restenosis allows reintervention before graft/stent failure and limb loss.
CaseMark